<DOC>
	<DOCNO>NCT00594698</DOCNO>
	<brief_summary>The purpose study evaluate preparation administration PB127 , echocardiographic image obtain PB127 administration , evaluate safety PB127 .</brief_summary>
	<brief_title>Familiarization Safety Study PB127 Ultrasound Contrast Agent</brief_title>
	<detailed_description>The primary objective clinical trial : 1 . To train potential Phase 3 investigational site preparation andministration PB127 2 . To train potential Phase 3 investigational site acquisition adequate image 3 . To collect additional safety information regard intravenous administration PB127 4 . To obtain large sample image obtain Acuson Sequoia ultrasound system .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Able provide write informed consent 2 . Scheduled stress echocardiography , SPECT nuclear image and/or coronary angiography within two week prior follow Study Day 1 3 . Adequate visualization myocardial segment least one image plane screen noncontrast echocardiogram 1 . Women pregnant lactate 2 . Known hypersensitivity know contraindication 1 . Dipyridamole 2 . Other ultrasound contrast agent 3 . Blood , blood product , albumin , egg , protein 3 . Use caffeine xanthine containing product within 24 hour prior PB127 MPE 4 . Frequent ( &gt; 60/hour ) symptomatic ventricular ectopics baseline 5 . Atrial fibrillation 6 . Permanent pacemaker defibrillator 7 . History : 1 . Complex ventricular arrhythmia 2 . Chronic hepatitis 3 . Liver disease characterize one following : current jaundice elevate bilirubin &gt; upper limit normal currently elevate hepatic enzyme &gt; 2X upper limit normal current previous hepatic viral infection 4 . Chronic obstructive pulmonary disease ( COPD ) , opinion Investigator , significant enough contraindicate dipyridamole 5 . Bronchospastic airway disease , opinion Investigator , significant enough contraindicate dipyridamole 6 . Coronary artery bypass graft ( CABG ) within 7 day prior Study Day 1 7 . Heart transplant 8 . Q wave myocardial infarction within 7 day prior Study Day 1 9 . Cardiac intervention surgery within 7 day prior Study Day 1 8 . Hypertension ( systolic blood pressure [ SBP ] &gt; 200 mmHg diastolic blood pressure [ DBP ] &gt; 110 mmHg ) 9 . Hypotension ( SBP &lt; 90 mmHg ) document within 24 hour prior Study Day 1 10 . Significant valvular disease 1 . Severe aortic stenosis ( &gt; 100 mmHg peak transvalvar gradient &lt; 0.6 cm2 estimate valve area ) 2 . Severe mitral regurgitation ( usual clinical criterion plus minus following : proximal isovelocity surface area [ PISA ] &gt; 1 cm2 , forward transmitral gradient &gt; 2 m/sec , unexplained systolic flow reversal blunt pulmonary vein ) 3 . Severe mitral stenosis ( &lt; 1.0 cm2 estimate valve area ) 11 . Congestive heart failure ( New York Heart Association [ NYHA ] Class IV ) ; NYHA class define Appendix D protocol ( see Appendix 16.1.1 ) 12 . Pulmonary edema within 7 day prior Study Day 1 13 . Resting oxygen saturation &lt; 90 % 14 . Pulmonary hypertension characterize estimate pulmonary artery systolic pressure &gt; 50 mmHg echo catheter criterion Study Day 1 15 . Unstable angina , Canadian Cardiovascular Society ( CCS ) Class IV severity , ongoing symptom and/or ongoing infusion intravenous nitroglycerin ; CCS grade criterion provide Appendix E protocol ( see Appendix 16.1.1 ) 16 . Second degree heart block great 17 . Use intravenous intracoronary contrast agent within 24 hour prior Study Day 1 18 . Medical condition circumstance would significantly decrease chance obtain reliable data achieve study objective , ie , drug dependence , psychiatric disorder , dementia , reason expect poor compliance Investigator 's instruction ; medical condition , associate illness , extenuate circumstance make unlikely patient complete clinical trial followup evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Perfusion</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Cardiac angiography</keyword>
	<keyword>SPECT</keyword>
</DOC>